Skip to main content

Anti-Rheumatic Rx

    RT @DrCassySims: How to prescribe methotrexate in a post-Roe era:

    Abstract #L09
    💊 6% of > 1,700 patients reporte
    1 year 6 months ago
    How to prescribe methotrexate in a post-Roe era: Abstract #L09 💊 6% of > 1,700 patients reported access issues to MTX -63% had a delay in filling script 🤰Excessive questions about possibility of pregnancy 🧑‍⚕️Pharmacy refused to fill #ACR22 #ACRbest @RheumNow
    The ability to prevent rheumatoid arthritis (RA) in individuals at risk of developing this condition is a holy grail in rheumatology. There is a long-history of interest in this area dating back to…
    A Year in Review
    RT @RHEUMarampa: HCQ tx thresholds study by Prof Garg:
    🔸HCQ >=500ng/ml: good threshold to detect adherence
    🔸HCQ
    1 year 6 months ago
    HCQ tx thresholds study by Prof Garg: 🔸HCQ >=500ng/ml: good threshold to detect adherence 🔸HCQ 750-1000ng/ml: effective thresholds to prevent flares 🔸CKD>=2: 4x ⬆️odds of HCQ>1500ng/ml (supraTx! dose adj.) Interesting data. Game changing?🧐 #ACR22 @RheumNow ABST#0344 #ACRBest https://t.co/GxlucrTeE5
    The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of…
    RT @synovialjoints: Adding MTX to Pegloticase for 52 wks in gout
    ◦ Improved response rate by 30%
    ◦ Reduced disconti
    1 year 6 months ago
    Adding MTX to Pegloticase for 52 wks in gout ◦ Improved response rate by 30% ◦ Reduced discontinuation rate by 40% ◦ Greater resolution of tophi by 20% ◦ Similar safety profile in MTX vs non-MTX groups Botson J, MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow https://t.co/le9ggUa2Xk
    RT @doctorRBC: NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant dec
    1 year 6 months ago
    NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy. *Numerical reduction in syndesmophytes 11% vs. 25% Abs#0546 @RheumNow #ACR22 #ACRBest https://t.co/pG5F3xdsh9